Search

Displaying results 4501 - 4510 of 10000 in total
  1. Drug

    GW 468816

    go.drugbank.com/drugs/DB05417
    Investigational

    It is designed to aid abstinence in people who have just quit smoking, delaying the time to relapse. It was undergoing phase II trials since December 2003.

    Categories: Receptors, N-Methyl-D-Aspartate, antagonists & inhibitors
  2. Drug

    Bacillus calmette-guerin substrain tice live antigen

    go.drugbank.com/drugs/DB10343
    ApprovedInvestigational

    It is administered to prevent the development of tuberculosis.

  3. Drug

    Tiapride

    go.drugbank.com/drugs/DB13025
    Investigational

    Tiapride is a selective D2 and D3 dopamine receptor blocker in the brain.

    Products: TIAPRID-NEURAX 100 MG, TIAPRID-NEURAX 200 MG
  4. Drug

    Vapreotide

    go.drugbank.com/drugs/DB04894
    Investigational

    It was being studied for the treatment of cancer.

  5. Drug

    Nirogacestat

    go.drugbank.com/drugs/DB12005
    ApprovedInvestigational

    It was previously granted breakthrough therapy, fast track, and orphan drug designations for the treatment of desmoid tumors, and the final approval was based on positive results obtained in the Phase … Desmoid tumors are typically characterized by aberrant activation in Notch signaling.

  6. Drug

    Poloxalene

    go.drugbank.com/drugs/DB11451
    InvestigationalVet approved

    It belongs to the family of Epoxides. These are compounds containing a cyclic ether with three ring atoms (one oxygen and two carbon atoms).

    Categories: Compounds used in a research, industrial, or household setting
  7. Drug

    Technetium Tc-99m etidronate

    go.drugbank.com/drugs/DB09411
    Approved

    Categories: Compounds used in a research, industrial, or household setting
  8. Drug

    AVI-4065

    go.drugbank.com/drugs/DB05620
    Investigational

    AVI-4065, a phosphorodiamidate Morpholino oligomer (PMO), is an investigational antisense HCV drug. It was developed by Sarepta Therapeutics, Inc. … After phase II trials it was cancelled due to lack of potency. [L2917]

  9. Drug

    ZD4407

    go.drugbank.com/drugs/DB06539
    Experimental

    It entered Phase 1 clinical trials for chronic obstructive pulmonary disease (COPD) in the United Kingdom but was discontinued during this phase in March 2003 … The drug ZD4407, an antiasthmatic developed by AstraZeneca, functions as a 5-lipoxygenase inhibitor.

  10. Drug

    Human interferon omega-1

    go.drugbank.com/drugs/DB05472
    Investigational

    It occurs naturally in the human body and is currently being manufactured by Intarcia through genetic engineering. … It has been investigated both in single and combination treatment. The biological activities of IFN-omega 1 and its physiological role are not known to date.